Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price raised by Piper Sandler from $70.00 to $83.00 in a report released on Tuesday morning, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on RARE. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a hold rating to a buy rating and set a $61.00 price objective for the company in a research report on Thursday, April 16th. SunTrust Banks upped their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $82.00 and gave the company a buy rating in a report on Friday, June 19th. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a report on Friday, June 19th. Canaccord Genuity boosted their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $85.00 and gave the company a buy rating in a research report on Friday, June 19th. Finally, Citigroup increased their target price on Ultragenyx Pharmaceutical from $53.00 to $66.00 and gave the stock a neutral rating in a report on Friday, May 8th. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $77.64.
Shares of NASDAQ RARE opened at $73.66 on Tuesday. Ultragenyx Pharmaceutical has a twelve month low of $31.99 and a twelve month high of $79.67. The stock has a market cap of $4.57 billion, a price-to-earnings ratio of -10.02 and a beta of 2.21. The company has a quick ratio of 4.49, a current ratio of 4.54 and a debt-to-equity ratio of 0.06. The company’s fifty day moving average is $71.53 and its 200-day moving average is $57.31.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.23). Ultragenyx Pharmaceutical had a negative return on equity of 60.65% and a negative net margin of 348.78%. The business had revenue of $36.31 million for the quarter, compared to the consensus estimate of $36.74 million. During the same quarter in the prior year, the firm posted ($1.82) earnings per share. The business’s revenue was up 99.8% on a year-over-year basis. On average, research analysts anticipate that Ultragenyx Pharmaceutical will post -6.43 EPS for the current fiscal year.
In other news, Director Matthew K. Fust sold 1,875 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $75.00, for a total value of $140,625.00. Following the sale, the director now directly owns 55,424 shares of the company’s stock, valued at approximately $4,156,800. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Theodore Alan Huizenga sold 2,461 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $71.00, for a total transaction of $174,731.00. Following the completion of the sale, the senior vice president now owns 18,719 shares of the company’s stock, valued at $1,329,049. The disclosure for this sale can be found here. Insiders sold 26,555 shares of company stock valued at $1,942,395 over the last three months. 8.20% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp raised its stake in Ultragenyx Pharmaceutical by 1.4% in the 1st quarter. State Street Corp now owns 2,229,351 shares of the biopharmaceutical company’s stock valued at $99,050,000 after acquiring an additional 30,604 shares during the period. Man Group plc boosted its position in Ultragenyx Pharmaceutical by 87.2% during the fourth quarter. Man Group plc now owns 96,143 shares of the biopharmaceutical company’s stock worth $4,107,000 after purchasing an additional 44,797 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 9.4% in the first quarter. Nuveen Asset Management LLC now owns 331,091 shares of the biopharmaceutical company’s stock valued at $14,710,000 after purchasing an additional 28,322 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Ultragenyx Pharmaceutical by 3.2% in the first quarter. Franklin Resources Inc. now owns 382,473 shares of the biopharmaceutical company’s stock valued at $16,993,000 after purchasing an additional 11,823 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of Ultragenyx Pharmaceutical by 84.9% in the first quarter. BNP Paribas Arbitrage SA now owns 39,832 shares of the biopharmaceutical company’s stock valued at $1,770,000 after purchasing an additional 18,286 shares during the period. Institutional investors own 99.91% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Article: Intrinsic Value and Stock Selection
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.